Retatrutide

Description

Retatrutide is a 39-amino acid peptide engineered based on the GIP peptide backbone, functioning as a novel triple-agonist peptide targeting the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Through its triple-agonist action, Retatrutide may demonstrate groundbreaking therapeutic efficacy.

Clinical Research Application

Type 2 diabetics

Retatrutide effectively activates the GLP-1 receptors present in the pancreas, heart, brain and blood vessels, resulting in a reduction in glucose concentration in the patient's fasting/post-meal blood. In patients with type 2 diabetes, Retatrutide shows clinically significant improvement in blood sugar control.

Obesity

Retatrutide works by delaying gastric emptying and decreasing appetite, thereby reducing calorie intake. Compared with existing GLP-1 single agonists or dual agonists, Retatrutide may have a stronger weight loss effect.

Phase I and II clinical trial results demonstrate that Retatrutide exhibits favorable efficacy and safety profiles. The phase Ⅲ clinical trial of Retatrutide for the treatment of type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and obesity is currently underway.